医療薬学
Online ISSN : 1882-1499
Print ISSN : 1346-342X
ISSN-L : 1346-342X
CYP遺伝子多型解析の病棟業務への応用
斉藤 嘉津彦, 清水 瓊子, 岡崎 正子, 伊林 至洋, 端 和夫, 前野 康次郎, 石井 清二, 土橋 和文, 島本 和明, 戸田 貴大, 黒澤 菜穂子, 大和田 栄治, 加藤 芳伸, 大山 徹, 梅津 有理, 千田 道洋, 有吉 範高, 鎌滝 哲也, 板谷 幸一
著者情報
ジャーナル フリー

2001 年 27 巻 3 号 p. 228-234

詳細
PDFをダウンロード (1010K)
メタデータをダウンロード RIS形式

(EndNote、Reference Manager、ProCite、RefWorksとの互換性あり)

BIB TEX形式

(BibDesk、LaTeXとの互換性あり)

テキスト
メタデータのダウンロード方法
発行機関連絡先
抄録

In recent years, genome science has undergone radical changes and numerous advances have led to the development of its use in medical practice. In particular developments in pharmacogenetics have demonstrated that genetic polymorphism is responsible for inter-individual differences in the drug metabolism. This study was conducted to identify the genetic polymorphisms of CYP 2C 9 and CYP 2 C19 using PCR-RFLP, and the application of a gene analysis was investigated in TDM or pharmaceutical management and in counseling services for patients. In a patient with the following pharmacokinetic parameters for phenytoin, for Km=6.69 μg/mL and Vmax = 3.62 mg/day/kg, and a largely decreased metabolic activity of CYP 2 C9 compared to the general population, the genetic differences in CYP 2 C9 could be determined in genomic DNA based on the patient's peripheral blood. Based on this finding, the effective dose for medication was calculated and administered to the patient. In addition, during medical consultations, both written and oral information in an easily comprehensible form could be given to patients with genetic polymorphism. These procedures allow a for the careful matching of the patient to the right medication and dose. This study indicates the possible application of a genetic analysis of CYP to “Evidence-Based Medicine” in the field of pharmaceutical management in order to control the dosage in individuals and to improve patient counseling.

著者関連情報
© 一般社団法人 日本医療薬学会
前の記事 次の記事
お気に入り & アラート

閲覧履歴
前身誌

病院薬学

このページを共有する
feedback
 Top